A/Prof Daniel Christ
Senior Research Fellow
Daniel holds degrees from the Swiss Federal Institute of Technology (ETH), where he graduated in 1999 with first class honors in Biochemistry, and from Cambridge University, where he completed his PhD in Sir Gregory Winter's laboratory at the MRC Laboratory of Molecular Biology (LMB). Winter had shown that in vitro evolution technology (such as phage display) can be used for the generation of therapeutic antibodies, initiating a multi-billion dollar biotechnology industry.
At Cambridge, Christ and Winter further developed monoclonal antibody technology, particularly in the field of domain antibodies. He was elected a Fellow of Trinity College (Cambridge University) at age 29 and was involved the foundation of Domantis Ltd (sold to GSK for £230m in 2006). Daniel joined Garvan in 2007 as head of the Antibody Therapeutics lab.
In the NewsNo more money and time down the drain say antibody experts in Nature - Feb 05, 2015
Start up company to commercialise antibody-stabilisation technology - Jan 15, 2015
Daniel Christ recognised with NHMRC Excellence Award - Nov 28, 2013
Garvan performs well in NHMRC grants round - Oct 24, 2012
Making biologically active yet stable antibodies - Jun 28, 2012
Awards and Honours
2012 - NHMRC CDF Fellowship Level 2
2008 - NHMRC CDF Fellowship Level 1
2002 - Fellow, Trinity College, Cambridge University
1999 - ERS PhD Scholarship, Trinity College, Cambridge University
1999 - Studer Prize (best graduate), Swiss Federal Institute of Technology (ETH)
1999 - Dipl Natw (MSc), Swiss Federal Institute of Technology (ETH) - Switzerland
Sabouri Z, Schofield P, Horikawa K, Spierings E, Kipling E, Randall K, Langley D, Roome B, Vazquez-Lombardi R, Rouet R, Hermes J, Chan T, Brink R, Dunn-Walters DK, Christ D* and Goodnow CC* Redemption of autoantibodies on anergic B cells by V-region glycosylation and mutation away from self-reactivity. Proc Natl Acad Sci U SA. 2014, in press. [*joint corresponding authors]
Rouet R and Christ D. Bispecific antibodies with native chain structure. Nature Biotechnology 2014; in press.
Gatto D, Wood K, Caminschi I, Murphy-Durland D, Schofield P, Christ D, Karupiah G and Brink R. The chemotactic receptor EBI2 regulates the homeostasis, localization and immune function of splenic dendritic cells. Nature Immunology 2013; 14(5):446-453.
Rouet R, Lowe D and Christ D. Stability Engineering of the human antibody repertoire. FEBS Letters – Protein Engineering Special Issue, 2013; 5793(13): 873-879.
Vazquez-Lombardi R, Roome B and Christ D. Molecular Engineering of Therapeutic Cytokines Antibodies 2013; 2: 426-451.
Schmitz I, Schneider C, Frohlich A, Frebel H, Christ D, Leonard WJ, Sparwasser T, Oxenius A, Freigang A and Kopf M. IL-21 Restricts Virus-driven Treg Cell Expansion in Chronic LCMV Infection PLOS Pathogens 2013; 9: e100336.
Dudgeon K, Rouet R and Christ D. Rapid prediction of expression and refolding yields using phage display. Prot. Engin. Des. Sel. 2013; 26(10):671-674.
Esteban O, Christ D and Stock D. Purification of molecular machines and nanomotors using phage derived monoclonal antibody fragments. Methods Mol. Biol. – Protein Nanotechnology 2013; 996:203-217.
Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D and Christ D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A. 2012; 109: 10879-10884. [ Editorial: http://www.pnas.org/content/109/27/10741.full.pdf ]
Rouet R, Dudgeon K, Schofield P, Lowe D, Jermutus L and Christ D. Expression of high affinity antibody fragments in bacteria. Nature Protoc. 2012; 7: 364-373.
Rouet R, Dudgeon K and Christ D. Generation of human single domain antibody repertoires by Kunkel mutagenesis. Methods Mol. Biol. 2012; 907: 195-209.
Dudgeon K, Famm K, Rouet R and Christ D. Selection of human VH single domains with improved biophysical properties by phage display. Methods Mol. Biol. 2012; 911:383-397.
McGuire H, Vogelzang A, Ma C, Hughes W, Silveira P, Tangye S, Christ D, Fulcher D, Falcone M and King C. A Subset of Interleukin-21+ Chemokine Receptor CCR9+ T Helper Cells Target Accessory Organs of the Digestive System in Autoimmunity. Immunity 2011; 34(4):602-615.
O'Toole SA, Machalek DA, Shearer RF, Millar EK, Nair R, Schofield P, McLeod D, Cooper CL, McNeil CM, McFarland A, Nguyen A, Ormandy CJ, Qiu MR, Rabinovich B, Martelotto LG, Vu D, Hannigan GE, Musgrove EA, Christ D, Sutherland RL, Watkins DN, and Swarbrick A. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res. 2011; 71(11):4002-4014.
Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L and Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv. Protein Chem. 2011; 84: 1-206.
McGuire H, Walters S, Vogelzang A, Lee CM, Webster KE, Sprent J, Christ D, Grey ST and King C. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 2011; 60(3):867-75.